Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Pharmacia Bextra Will Be Premium Priced, In Pharmacies Feb. 15

Executive Summary

Pharmacia/Pfizer's COX-2 inhibitor Bextra will be launched at a 10% price premium over Celebrex and Vioxx

You may also be interested in...



Pfizer To Re-Do Celebrex GI Outcome Study After Pharmacia Merger

Pfizer's post-merger plans for Celebrex include a second gastrointestinal outcomes study to demonstrate a safety benefit for the COX-2 inhibitor

Pfizer To Re-Do Celebrex GI Outcome Study After Pharmacia Merger

Pfizer's post-merger plans for Celebrex include a second gastrointestinal outcomes study to demonstrate a safety benefit for the COX-2 inhibitor

Pfizer Geodon QT Drug Contraindication Expanded, Clarified In New Labeling

Pfizer's Geodon should not be used by patients taking drugs that have a contraindication or boxed or bolded warning about QT prolongation, a labeling revision for the antypsychotic states

Related Content

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel